vs
IDEAYA Biosciences, Inc.（IDYA）与Sarepta Therapeutics, Inc.（SRPT）财务数据对比。点击上方公司名可切换其他公司
Sarepta Therapeutics, Inc.的季度营收约是IDEAYA Biosciences, Inc.的1.8倍（$369.6M vs $207.8M），IDEAYA Biosciences, Inc.净利率更高（57.4% vs -111.5%，领先168.9%），IDEAYA Biosciences, Inc.自由现金流更多（$142.2M vs $127.6M）
IDEAYA Biosciences是一家临床阶段生物技术企业，专注于肿瘤学领域，研发针对基因定义癌症的靶向疗法及合成致死治疗方案，推进多肿瘤类型的候选药物管线开发，与行业伙伴合作提升全球创新癌症治疗方案的可及性。
Sarepta Therapeutics是一家总部位于美国马萨诸塞州剑桥的生物医药企业，专注于医学研究与药物研发。公司成立于1980年，前身为AntiVirals，后续先后更名为AVI BioPharma及现名，截至2023年已有四款获批上市药物，在相关疾病治疗领域深耕技术创新。
IDYA vs SRPT — 直观对比
营收规模更大
SRPT
是对方的1.8倍
$207.8M
净利率更高
IDYA
高出168.9%
-111.5%
自由现金流更多
IDYA
多$14.6M
$127.6M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $207.8M | $369.6M |
| 净利润 | $119.2M | $-412.2M |
| 毛利率 | — | — |
| 营业利润率 | 52.2% | -111.4% |
| 净利率 | 57.4% | -111.5% |
| 营收同比 | — | -42.1% |
| 净利润同比 | 330.1% | -359.2% |
| 每股收益（稀释后） | $1.33 | $-3.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDYASRPT
| Q4 25 | — | $369.6M | ||
| Q3 25 | $207.8M | $370.0M | ||
| Q2 25 | — | $513.1M | ||
| Q1 25 | — | $611.5M | ||
| Q4 24 | — | $638.2M | ||
| Q3 24 | $0 | $429.8M | ||
| Q2 24 | $0 | $360.5M | ||
| Q1 24 | $0 | $359.5M |
净利润IDYASRPT
| Q4 25 | — | $-412.2M | ||
| Q3 25 | $119.2M | $-50.6M | ||
| Q2 25 | — | $196.9M | ||
| Q1 25 | — | $-447.5M | ||
| Q4 24 | — | $159.0M | ||
| Q3 24 | $-51.8M | $33.6M | ||
| Q2 24 | $-52.8M | $6.5M | ||
| Q1 24 | $-39.6M | $36.1M |
毛利率IDYASRPT
| Q4 25 | — | — | ||
| Q3 25 | — | 59.3% | ||
| Q2 25 | — | 70.3% | ||
| Q1 25 | — | 77.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 78.7% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.9% |
营业利润率IDYASRPT
| Q4 25 | — | -111.4% | ||
| Q3 25 | 52.2% | -27.9% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | -49.1% | ||
| Q4 24 | — | 25.3% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | 9.7% |
净利率IDYASRPT
| Q4 25 | — | -111.5% | ||
| Q3 25 | 57.4% | -13.7% | ||
| Q2 25 | — | 38.4% | ||
| Q1 25 | — | -73.2% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 10.0% |
每股收益（稀释后）IDYASRPT
| Q4 25 | — | $-3.92 | ||
| Q3 25 | $1.33 | $-0.50 | ||
| Q2 25 | — | $1.89 | ||
| Q1 25 | — | $-4.60 | ||
| Q4 24 | — | $1.56 | ||
| Q3 24 | $-0.60 | $0.34 | ||
| Q2 24 | $-0.68 | $0.07 | ||
| Q1 24 | $-0.53 | $0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $786.9M | $939.6M |
| 总债务越低越好 | — | $829.0M |
| 股东权益账面价值 | $1.1B | $1.1B |
| 总资产 | $1.2B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.73× |
8季度趋势，按日历期对齐
现金及短期投资IDYASRPT
| Q4 25 | — | $939.6M | ||
| Q3 25 | $786.9M | $851.0M | ||
| Q2 25 | — | $800.1M | ||
| Q1 25 | — | $522.8M | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $920.0M | $1.2B | ||
| Q2 24 | $701.7M | $1.5B | ||
| Q1 24 | $698.8M | $1.4B |
总债务IDYASRPT
| Q4 25 | — | $829.0M | ||
| Q3 25 | — | $140.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
股东权益IDYASRPT
| Q4 25 | — | $1.1B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $931.7M | $1.1B | ||
| Q1 24 | $935.3M | $961.2M |
总资产IDYASRPT
| Q4 25 | — | $3.3B | ||
| Q3 25 | $1.2B | $3.5B | ||
| Q2 25 | — | $3.7B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | $1.2B | $3.6B | ||
| Q2 24 | $973.7M | $3.4B | ||
| Q1 24 | $961.5M | $3.2B |
负债/权益比IDYASRPT
| Q4 25 | — | 0.73× | ||
| Q3 25 | — | 0.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 1.14× | ||
| Q1 24 | — | 1.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.2M | $131.2M |
| 自由现金流经营现金流 - 资本支出 | $142.2M | $127.6M |
| 自由现金流率自由现金流/营收 | 68.4% | 34.5% |
| 资本支出强度资本支出/营收 | 0.0% | 1.0% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $13.5M | $-307.5M |
8季度趋势，按日历期对齐
经营现金流IDYASRPT
| Q4 25 | — | $131.2M | ||
| Q3 25 | $142.2M | $-14.6M | ||
| Q2 25 | — | $261.3M | ||
| Q1 25 | — | $-583.4M | ||
| Q4 24 | — | $92.0M | ||
| Q3 24 | $-49.2M | $-70.7M | ||
| Q2 24 | $-32.9M | $14.9M | ||
| Q1 24 | $-43.8M | $-242.1M |
自由现金流IDYASRPT
| Q4 25 | — | $127.6M | ||
| Q3 25 | $142.2M | $-37.5M | ||
| Q2 25 | — | $229.5M | ||
| Q1 25 | — | $-627.1M | ||
| Q4 24 | — | $54.0M | ||
| Q3 24 | $-49.7M | $-108.0M | ||
| Q2 24 | $-33.9M | $-14.2M | ||
| Q1 24 | $-45.1M | $-274.5M |
自由现金流率IDYASRPT
| Q4 25 | — | 34.5% | ||
| Q3 25 | 68.4% | -10.1% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | -102.5% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | -25.1% | ||
| Q2 24 | — | -3.9% | ||
| Q1 24 | — | -76.4% |
资本支出强度IDYASRPT
| Q4 25 | — | 1.0% | ||
| Q3 25 | 0.0% | 6.2% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | 8.7% | ||
| Q2 24 | — | 8.1% | ||
| Q1 24 | — | 9.0% |
现金转化率IDYASRPT
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | 1.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | -2.10× | ||
| Q2 24 | — | 2.31× | ||
| Q1 24 | — | -6.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDYA
暂无分部数据
SRPT
| Pmo Products | $202.5M | 55% |
| Elevidys | $110.4M | 30% |
| Other | $56.7M | 15% |
